Novo Nordisk’s Wegovy Gets EU Thumbs Up But Launch Will Wait
Based On Positive Phase III Data
Wegovy is set to join Saxenda as the company’s second EU approved drug for obesity, helping it corner the region’s weight-management market, once the company gets its supply back on track.
You may also be interested in...
Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.
The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration.
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.